Anika Therapeutics, Inc. (ANIK) Stock

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.

Anika Therapeutics, Inc. is led by CEO Stephen D. Griffin, employs 288 people, headquartered in US, publicly traded since 1993.

Anika Therapeutics, Inc. (ANIK) stock trades at $21.00 with a market capitalization of $281.04M. The stock is valued at a price-to-earnings (P/E) ratio of -19.58, price-to-book of 1.38, price-to-sales of 1.70. Over the past 52 weeks the stock has ranged between $8.37 and $22.88, and currently trades 8.2% below its 52-week high.

On profitability, Anika Therapeutics, Inc. generates a return on equity (ROE) of -7.69%, return on capital employed of -7.69%, an operating margin of -9.73%, a net profit margin of -9.52%.

Official website: www.anika.com